Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2023, with a report date of July 28, 2023. The document serves as a transaction notification regarding a sale of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Transaction Type | Instrument | Volume | Price per Share | Total Value (Approx.) |
|---|---|---|---|---|
| Sale | Ordinary Shares (31 1/4 pence each) | 9,728 | £14.1113 | £137,274.73 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction executed on July 27, 2023, on the London Stock Exchange (XLON).
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a mandatory disclosure of a transaction by Sally Jackson, SVP, Global Communications and CEO Office.
Key Facts for Investor Verification
- The transaction involved the sale of 9,728 ordinary shares by Sally Jackson.
- The transaction occurred on July 27, 2023, at a price of £14.1113 per share.
- This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for financial data.